Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LEXX NYSEAMERICAN:MTNB OTCMKTS:OTLC NASDAQ:ZIVO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLEXXLexaria Bioscience$0.63-2.3%$0.82$0.46▼$1.55$15.52M0.37191,242 shs50,695 shsMTNBMatinas Biopharma$0.640.0%$0.58$0.48▼$3.09$4.13M1.6129,497 shs11,470 shsOTLCOncotelic Therapeutics$0.04-0.8%$0.04$0.02▼$0.11$17.07M-0.54275,034 shs24,998 shsZIVOZIVO Bioscience$4.00$5.80$1.11▼$19.65$16.01M0.043,892 shs4,752 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLEXXLexaria Bioscience-5.00%-2.78%-35.28%-11.63%-38.39%MTNBMatinas Biopharma-5.15%-0.83%+28.36%+9.32%-8.90%OTLCOncotelic Therapeutics+5.43%+3.74%+4.58%-41.74%-34.13%ZIVOZIVO Bioscience0.00%+13.31%+11.11%-60.98%-75.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLEXXLexaria Bioscience$0.63-2.3%$0.82$0.46▼$1.55$15.52M0.37191,242 shs50,695 shsMTNBMatinas Biopharma$0.640.0%$0.58$0.48▼$3.09$4.13M1.6129,497 shs11,470 shsOTLCOncotelic Therapeutics$0.04-0.8%$0.04$0.02▼$0.11$17.07M-0.54275,034 shs24,998 shsZIVOZIVO Bioscience$4.00$5.80$1.11▼$19.65$16.01M0.043,892 shs4,752 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLEXXLexaria Bioscience-5.00%-2.78%-35.28%-11.63%-38.39%MTNBMatinas Biopharma-5.15%-0.83%+28.36%+9.32%-8.90%OTLCOncotelic Therapeutics+5.43%+3.74%+4.58%-41.74%-34.13%ZIVOZIVO Bioscience0.00%+13.31%+11.11%-60.98%-75.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLEXXLexaria Bioscience 2.00Hold$1.50139.62% UpsideMTNBMatinas Biopharma 0.00N/AN/AN/AOTLCOncotelic Therapeutics 0.00N/AN/AN/AZIVOZIVO Bioscience 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest MTNB, ZIVO, OTLC, and LEXX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2026LEXXLexaria Bioscience Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLEXXLexaria Bioscience$710K21.86N/AN/A$0.13 per share4.82MTNBMatinas Biopharma$1.10M3.76N/AN/A$0.75 per share0.86OTLCOncotelic Therapeutics$70K243.91$0.55 per share0.07$0.59 per share0.07ZIVOZIVO Bioscience$15.85K1,009.97N/AN/A($0.81) per share-4.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLEXXLexaria Bioscience-$11.90M-$0.47N/AN/AN/A-1,685.84%-206.02%-162.53%7/13/2026 (Estimated)MTNBMatinas Biopharma-$10.35M-$3.89N/AN/AN/AN/A-163.98%-102.52%N/AOTLCOncotelic Therapeutics$249.28M$0.590.07N/AN/AN/A350.62%210.10%N/AZIVOZIVO Bioscience-$7.78M-$2.18N/AN/AN/AN/AN/A-2,240.92%5/13/2026 (Estimated)Latest MTNB, ZIVO, OTLC, and LEXX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/3/2026N/AZIVOZIVO Bioscience-$0.30N/AN/AN/A$0.13 millionN/A4/15/2026Q4 2025OTLCOncotelic TherapeuticsN/A$0.59N/A$0.59N/AN/A4/13/2026Q2 2026LEXXLexaria Bioscience-$0.0950-$0.06+$0.0350-$0.06$0.05 million$0.02 million3/31/2026Q4 2025MTNBMatinas BiopharmaN/A-$0.26N/A-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthLEXXLexaria BioscienceN/AN/AN/AN/AN/AMTNBMatinas BiopharmaN/AN/AN/AN/AN/AOTLCOncotelic TherapeuticsN/AN/AN/AN/AN/AZIVOZIVO BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLEXXLexaria BioscienceN/A26.8426.84MTNBMatinas BiopharmaN/A2.792.79OTLCOncotelic Therapeutics0.010.070.07ZIVOZIVO BioscienceN/A0.170.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLEXXLexaria Bioscience13.06%MTNBMatinas Biopharma11.77%OTLCOncotelic TherapeuticsN/AZIVOZIVO Bioscience12.83%Insider OwnershipCompanyInsider OwnershipLEXXLexaria Bioscience8.39%MTNBMatinas Biopharma4.60%OTLCOncotelic Therapeutics39.22%ZIVOZIVO Bioscience48.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLEXXLexaria Bioscience724.79 million22.71 millionNot OptionableMTNBMatinas Biopharma306.41 million6.11 millionN/AOTLCOncotelic Therapeutics20443.48 million269.55 millionNot OptionableZIVOZIVO Bioscience104.00 million2.91 millionNot OptionableMTNB, ZIVO, OTLC, and LEXX HeadlinesRecent News About These CompaniesZivo Bioscience Inc. WtApril 11, 2026 | barrons.comZIVO Bioscience Provides Special Letter to ShareholdersMarch 27, 2026 | businesswire.comMaxim Group Reaffirms Their Hold Rating on Zivo Bioscience (ZIVO)December 15, 2025 | theglobeandmail.comZIVO Bioscience releases letter to shareholdersSeptember 14, 2025 | wattagnet.comWZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic BusinessesSeptember 10, 2025 | businesswire.comZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in PoultryJune 20, 2025 | businesswire.comUniversity of Delaware Study Identifies Optimal Formulation of ZIVO’s Active Ingredients for Further Testing to Mitigate Avian Influenza in PoultryMay 7, 2025 | finance.yahoo.comUniversity of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in PoultryMay 6, 2025 | businesswire.comZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in PoultryFebruary 6, 2025 | businesswire.comZivo Bioscience issues new shares, raises $1.5 millionJanuary 28, 2025 | msn.comTuesday's Insider Activity: Top Buys and Sells in US Stocks RevealedJanuary 1, 2025 | investing.comZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian InfluenzaDecember 20, 2024 | businesswire.comZIVO Stock Earnings: Zivo Bioscience Reported Results for Q4 2023March 18, 2024 | investorplace.comHarmony Biosciences HoldingsMarch 4, 2024 | forbes.comRegencell Bioscience Holdings Ltd RGCFebruary 1, 2024 | morningstar.comMZIVO Bioscience Announces Uplisting to OTCQB MarketJanuary 29, 2024 | finance.yahoo.comIdeaya BiosciencesJanuary 18, 2024 | forbes.comDare Bioscience Inc DAREJanuary 14, 2024 | morningstar.comMZivo Bioscience Inc (ZIVO) USD0.001November 11, 2023 | hl.co.ukZivo Bioscience (ZIVO) Price Target Increased by 500.00% to 36.72November 1, 2023 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMTNB, ZIVO, OTLC, and LEXX Company DescriptionsLexaria Bioscience NASDAQ:LEXX$0.63 -0.01 (-2.29%) As of 11:07 AM Eastern This is a fair market value price provided by Massive. Learn more.Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.Matinas Biopharma NYSEAMERICAN:MTNB$0.64 0.00 (-0.02%) As of 10:09 AM EasternMatinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.Oncotelic Therapeutics OTCMKTS:OTLC$0.04 0.00 (-0.77%) As of 09:43 AM EasternOncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of Artemisinin based products and support technologies. Oncotelic Therapeutics, Inc. is based in Agoura Hills, California.ZIVO Bioscience NASDAQ:ZIVO$4.00 0.00 (0.00%) As of 05/7/2026 02:54 PM EasternZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
